Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome

NCT04810611 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT04810611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04810611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
June 18, 2021
Completion date
April 19, 2024
Enrollment
33 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes